PMID- 16113603
OWN - NLM
STAT- MEDLINE
DCOM- 20051207
LR  - 20191109
IS  - 1524-9557 (Print)
IS  - 1524-9557 (Linking)
VI  - 28
IP  - 5
DP  - 2005 Sep-Oct
TI  - Tumor vaccination by Salmonella typhimurium after transformation with a 
      eukaryotic expression vector in mice: impact of a Salmonella typhimurium gene 
      interfering with MHC class I presentation.
PG  - 467-79
AB  - Transformed attenuated Salmonella typhimurium (ST) have been suggested as an 
      efficient means of tumor vaccination. However, ST themselves might be 
      immunosuppressive, and the question has arisen as to whether this impedes 
      vaccination efficacy even if ST are transformed with a eukaryotic expression 
      vector such that "tumor antigen" will be transcribed by the host. The question 
      was evaluated using a mutant SL7207, where the yej operon, which interferes with 
      MHC I-mediated presentation, had been inactivated (SL7207DeltayejE). Mice were 
      vaccinated with SL7207 or SL7207DeltayejE transformed with a eukaryotic 
      expression vector carrying the lacZ or the gp100 gene and later received 
      lacZ-transfected RENCA or YC8 or gp100-expressing B16F1 tumor cells. In 
      vaccinated mice, tumor growth started with a delay and some animals remained 
      tumor-free; however, the tumor growth rate remained unaltered. No significant 
      difference was seen between SL7207DeltayejE versus SL7207 vaccinated mice. The 
      latter finding contrasted with ex vivo analyses where vaccination with 
      SL7207DeltayejE, compared with SL7207, induced a significantly stronger response, 
      including nonadaptive defense mechanisms. The failure to detect a superior 
      vaccination efficacy of SL7207DeltayejE in vivo could be attributed to a stronger 
      effect of the yej operon on MHC-mediated antigen presentation when driven by a 
      prokaryotic promoter. Also, additional Salmonella genes apparently interfere with 
      maintenance of a sustained immune response. Thus, the immunosuppressive yej 
      operon affects innate and adaptive immunity. However, when ST are carriers for 
      eukaryotic-expressed tumor antigens, yej does not severely hamper induction of an 
      immune response.
FAU - Hummel, Susanne
AU  - Hummel S
AD  - Department of Tumor Progression and Tumor Defense, German Cancer Research Center, 
      Heidelberg, Germany. m.zoeller@dkfz.de
FAU - Apte, Ron N
AU  - Apte RN
FAU - Qimron, Udi
AU  - Qimron U
FAU - Vitacolonna, Mario
AU  - Vitacolonna M
FAU - Porgador, Angel
AU  - Porgador A
FAU - Zoller, Margot
AU  - Zoller M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Cancer Vaccines)
RN  - 0 (DNA, Complementary)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/chemistry
MH  - Cancer Vaccines/*therapeutic use
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - DNA, Complementary/metabolism
MH  - Dendritic Cells/cytology
MH  - Flow Cytometry/methods
MH  - *Genes, MHC Class I
MH  - Genetic Vectors
MH  - Immunosuppressive Agents/therapeutic use
MH  - Immunotherapy
MH  - In Vitro Techniques
MH  - Killer Cells, Lymphokine-Activated/cytology
MH  - Lymph Nodes/cytology
MH  - Lymphocyte Activation
MH  - Lymphocytes/cytology
MH  - Macrophages/metabolism
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Monocytes/metabolism
MH  - Mutation
MH  - Salmonella typhimurium/*metabolism
MH  - T-Lymphocytes, Cytotoxic/cytology
MH  - Time Factors
EDAT- 2005/08/23 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/08/23 09:00
PHST- 2005/08/23 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/08/23 09:00 [entrez]
AID - 00002371-200509000-00006 [pii]
AID - 10.1097/01.cji.0000170359.92090.8b [doi]
PST - ppublish
SO  - J Immunother. 2005 Sep-Oct;28(5):467-79. doi: 10.1097/01.cji.0000170359.92090.8b.